Acurx Pharmaceuticals LLC

10-Year Study

ACXP.US · Healthcare · US · Common Stock

Executive Summary: Acurx Pharmaceuticals LLC has compounded at -55.7% annually over the last 10 years, with a maximum drawdown of 98.8% and an annualized volatility of 129.5%.

1Y CAGR
-71.1%
3Y CAGR
-66.8%
5Y CAGR
-55.7%
10Y CAGR
-55.7%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
98.8%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
-0.14
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
-0.50
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
150.8%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · +0.0%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2025 · -84.7%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
0%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-5.0-36.6147.3-32.9————————-0.0%
2025-10.2-2.9-45.110.3-9.531.4-36.2-29.1-7.117.0-22.7-35.8-84.7%
2024-14.6-12.2-14.6-10.214.1-10.4-4.01.9-13.6-1.1-33.5-34.9-78.7%
2023-9.5-8.14.5-13.63.7-14.5-23.4-4.9-22.3256.7-34.28.8-3.8%
2022-3.7-12.5-9.913.7-27.940.9-5.5-2.5-14.02.73.624.8-7.9%
2021——————-11.0-9.0-0.6-2.7-4.0-10.0-32.3%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 129.5%. The dominant macroeconomic risk driver is VEA.US, accounting for 31.6% of variance. Idiosyncratic stock-specific factors contribute 37.7%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2021-06-0110000
2021-07-018902.82131661442
2021-08-018103.44827586207
2021-09-018056.426332288401
2021-10-017836.990595611285
2021-11-017523.5109717868345
2021-12-016772.727272727274
2022-01-016520.37617554859
2022-02-015703.761755485893
2022-03-015141.065830721003
2022-04-015846.394984326019
2022-05-014216.300940438871
2022-06-015940.438871473355
2022-07-015611.285266457679
2022-08-015470.219435736677
2022-09-014702.194357366771
2022-10-014827.586206896552
2022-11-015000
2022-12-016238.244514106584
2023-01-015642.633228840126
2023-02-015188.087774294672
2023-03-015423.19749216301
2023-04-014686.520376175548
2023-05-014858.934169278998
2023-06-014153.605015673981
2023-07-013181.8181818181824
2023-08-013025.078369905956
2023-09-012351.0971786833857
2023-10-018385.579937304075
2023-11-015517.241379310346
2023-12-016003.134796238244
2024-01-015125.391849529781
2024-02-014498.432601880878
2024-03-013840.12539184953
2024-04-013448.2758620689656
2024-05-013934.1692789968656
2024-06-013526.6457680250783
2024-07-013385.579937304076
2024-08-013448.2758620689656
2024-09-012978.0564263322885
2024-10-012946.7084639498435
2024-11-011959.2476489028213
2024-12-011275.8620689655172
2025-01-011145.7680250783699
2025-02-011112.8526645768025
2025-03-01611.2852664576802
2025-04-01673.9811912225706
2025-05-01609.717868338558
2025-06-01800.9404388714735
2025-07-01510.9717868338558
2025-08-01362.0689655172414
2025-09-01336.2068965517242
2025-10-01393.4169278996865
2025-11-01304.0752351097179
2025-12-01195.14106583072103
2026-01-01185.34482758620692
2026-02-01117.55485893416929
2026-03-01290.7523510971787
2026-04-01195.14106583072103
Annual Return Matrix
YearAnnual Return
2022-0.0789169173802361
2023-0.03768844221105527
2024-0.787467362924282
2025-0.847051597051597
20260
Total Factor Risk
1.2950886598982594
VTI.US Exposure
0.16364387391669713
VEA.US Exposure
0.31592591299818834
VWO.US Exposure
-0.02770922790285157
QQQ.US Exposure
0.022901752966811115
VTV.US Exposure
-0.02308138238304601
IJR.US Exposure
-0.000535982099223953
QUAL.US Exposure
-0.0045611295023057
SHV.US Exposure
0.028196841027471647
TLT.US Exposure
0.055491345666202424
LQD.US Exposure
0.0021007262051164657
HYG.US Exposure
-0.0042031748598517545
GLD.US Exposure
-0.00550976081982616
USO.US Exposure
0.0260005837489532
VNQ.US Exposure
-0.016138076341069858
BTC-USD.CC Exposure
0.003299368816323102
CPER.US Exposure
0.006209141110947547
VIX.INDX Exposure
-0.004855531911214658
UUP.US Exposure
0.08636102322680617
TIP.US Exposure
-0.0009572732518104293
Idiosyncratic Exposure
0.3774209693876829
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
129.5%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$11.1M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-15.7%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-44.6%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
84.8% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
-1.16
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is Acurx Pharmaceuticals LLC a high-risk investment?

Acurx Pharmaceuticals LLC (ACXP.US) has an annualized volatility of 129.5% and experienced a maximum drawdown of 98.8% over the last 10 years. Its primary macro risk driver is VEA.US.

What is the 10-year return of ACXP.US?

Over the past 10 years, ACXP.US has generated a Compound Annual Growth Rate (CAGR) of -55.7%. It has had a positive return in 0% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Acurx Pharmaceuticals LLC

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest